由磷脂双层组成的脂质体是用于药物递送的有效纳米载体，因为它们可以封装亲水性和亲脂性药物。传统的癌症治疗有时会涉及相当大的毒性和药物不良反应（ADR），这限制了其临床价值。尽管脂质体有望解决这些问题，但临床试验却揭示了其显着的局限性，包括稳定性、靶向分布和扩展挑战。最近的临床试验侧重于增强脂质体配方，以提高治疗效果，同时最大限度地减少负面影响。值得注意的是，Doxil 等脂质体药物的批准证明了它们在癌症治疗中的潜力。然而，脂质体制备的复杂性和全面监管批准的要求仍然是重大障碍。目前的临床试验更新表明，为了解决这些问题，我们正在继续努力改善脂质体稳定性、靶向机制和有效负载能力。脂质体药物递送在癌症治疗中的未来取决于解决这些挑战，以便为患者提供更有效、更安全的治疗选择。

Liposomes, made up of phospholipid bilayers, are efficient nanocarriers for drug delivery because they can encapsulate both hydrophilic and lipophilic drugs. Conventional cancer treatments sometimes involve considerable toxicities and adverse drug reactions (ADRs), which limits their clinical value. Despite liposomes' promise in addressing these concerns, clinical trials have revealed significant limitations, including stability, targeted distribution, and scaling challenges. Recent clinical trials have focused on enhancing liposome formulations to increase therapeutic efficacy while minimizing negative effects. Notably, the approval of liposomal medications like Doxil demonstrates their potential in cancer treatment. However, the intricacy of liposome preparation and the requirement for comprehensive regulatory approval remain substantial impediments. Current clinical trial updates show continued efforts to improve liposome stability, targeting mechanisms, and payload capacity in order to address these issues. The future of liposomal drug delivery in cancer therapy depends on addressing these challenges in order to provide patients with more effective and safer treatment alternatives.